These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18394961)

  • 41. Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system.
    Couplan E; Le Cann M; Le Foll C; Corporeau C; Blondel M; Delarue J
    Biotechnol J; 2009 Aug; 4(8):1190-7. PubMed ID: 19557793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
    Opel D; Westhoff MA; Bender A; Braun V; Debatin KM; Fulda S
    Cancer Res; 2008 Aug; 68(15):6271-80. PubMed ID: 18676851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
    Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
    FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
    Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2011 May; 21(5):803-6. PubMed ID: 21434841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.
    Ferrari N; Seguin R; Renzi P
    Future Med Chem; 2011 Oct; 3(13):1647-62. PubMed ID: 21942254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
    J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
    Rexer BN; Ghosh R; Arteaga CL
    Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies of therapeutic complement inhibition.
    Mollnes TE; Kirschfink M
    Mol Immunol; 2006 Jan; 43(1-2):107-21. PubMed ID: 16011851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.
    Rolan P; Hutchinson M; Johnson K
    Expert Opin Pharmacother; 2009 Dec; 10(17):2897-904. PubMed ID: 19929708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
    Medina-Tato DA; Ward SG; Watson ML
    Immunology; 2007 Aug; 121(4):448-61. PubMed ID: 17614878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.
    Ghigo A; Damilano F; Braccini L; Hirsch E
    Bioessays; 2010 Mar; 32(3):185-196. PubMed ID: 20162662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3Kγ.
    Basset C; Guillermet-Guibert J
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):351-353. PubMed ID: 28583586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic antibodies: A new era in the treatment of respiratory diseases?
    Sécher T; Guilleminault L; Reckamp K; Amanam I; Plantier L; Heuzé-Vourc'h N
    Pharmacol Ther; 2018 Sep; 189():149-172. PubMed ID: 29730443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
    Van Dort ME; Galbán S; Nino CA; Hong H; Apfelbaum AA; Luker GD; Thurber GM; Atangcho L; Besirli CG; Ross BD
    ACS Med Chem Lett; 2017 Aug; 8(8):808-813. PubMed ID: 28835793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Interferon inducers in treating acute respiratory diseases: problems and prospects].
    Lobzin IuV; L'vov NI
    Voen Med Zh; 2001 Nov; 322(11):41-50. PubMed ID: 11871061
    [No Abstract]   [Full Text] [Related]  

  • 57. Therapeutics bibliography for clinical pharmacists: respiratory disease.
    Porter RS
    Am J Hosp Pharm; 1980 Jun; 37(6):862-4. PubMed ID: 6994498
    [No Abstract]   [Full Text] [Related]  

  • 58. Key developments in respiratory medicine.
    Sutcliffe AM; Knox AJ
    Practitioner; 2006 Apr; 250(1681):185-6, 189-92. PubMed ID: 16669351
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapeutic delivery of RNA effectors: diseases affecting the respiratory system.
    Kandil R; Merkel M
    Pharmazie; 2016 Jan; 71(1):21-6. PubMed ID: 26867349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory twins from PI3K gang brought to justice?
    Thompson PE; Jennings IG; Pinson JA
    Chem Biol; 2010 Feb; 17(2):101-2. PubMed ID: 20189098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.